Posted 20 July 2017 - 13:05
Posted 20 July 2017 - 13:05
News
Vaccine for gonorrhoea shows promise
A vaccine for gonorrhoea offers hope in the fight against drug-resistant sexually transmitted infections, a study has found.
A vaccine for gonorrhoea offers hope in the fight against drug-resistant sexually transmitted infections, a study has found
A vaccine to protect against gonorrhoea offers hope in the fight against drug-resistant sexually transmitted infections, according to a study of 14,000 people.
Researchers at the University of Auckland in New Zealand examined data from a mass meningococcal group B (MeNZB) vaccination campaign in the country in 2004-2006.
They looked specifically at people aged 15-30 who had been diagnosed with gonorrhoea or chlamydia, or both, at 11 sexual health clinics and who were eligible for the MeNZB vaccine programme.
Vaccinated individuals were shown to be 41% less likely to have gonorrhoea than non-vaccinated people.
Moderate protection
Taking into account factors such as ethnicity, deprivation, geographical
A vaccine for gonorrhoea offers hope in the fight against drug-resistant sexually transmitted infections, a study has found
against gonorrhoea, a study shows. Picture: iStock
A vaccine to protect against gonorrhoea offers hope in the fight against drug-resistant sexually transmitted infections, according to a study of 14,000 people.
Researchers at the University of Auckland in New Zealand examined data from a mass meningococcal group B (MeNZB) vaccination campaign in the country in 2004-2006.
They looked specifically at people aged 15-30 who had been diagnosed with gonorrhoea or chlamydia, or both, at 11 sexual health clinics and who were eligible for the MeNZB vaccine programme.
Vaccinated individuals were shown to be 41% less likely to have gonorrhoea than non-vaccinated people.
Moderate protection
Taking into account factors such as ethnicity, deprivation, geographical area and gender, the researchers conclude that having previously received the MeNZB vaccine reduced the incidence of gonorrhoea by approximately 31%.
Lead author Helen Petousis-Harris said: ‘Our findings provide experimental evidence and a proof of principle that a meningococcal group B vaccine could offer moderate cross-protection against gonorrhoea.'
Petousis-Harris H et al (2017). Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study. The Lancet Infectious Diseases. doi.org/10.1016/S0140-6736(17)31449-6